Works by Infante, Jeffrey R

Results: 37
    1
    2
    3
    4
    5
    6
    7
    8
    9

    Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.

    Published in:
    Journal of Clinical Pharmacology, 2015, v. 55, n. 4, p. 392, doi. 10.1002/jcph.437
    By:
    • Suttle, A. Benjamin;
    • Grossmann, Kenneth F.;
    • Ouellet, Daniele;
    • Richards‐Peterson, Lauren E.;
    • Aktan, Gursel;
    • Gordon, Michael S.;
    • LoRusso, Patricia M.;
    • Infante, Jeffrey R.;
    • Sharma, Sunil;
    • Kendra, Kari;
    • Patel, Manish;
    • Pant, Shubham;
    • Arkenau, Hendrik‐Tobias;
    • Middleton, Mark R.;
    • Blackman, Samuel C.;
    • Botbyl, Jeff;
    • Carson, Stanley W.
    Publication type:
    Article
    10
    11
    12

    A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.

    Published in:
    2015
    By:
    • Bendell, Johanna C.;
    • Kelley, Robin K.;
    • Shih, Kent C.;
    • Grabowsky, Jennifer A.;
    • Bergsland, Emily;
    • Jones, Suzanne;
    • Martin, Thomas;
    • Infante, Jeffrey R.;
    • Mischel, Paul S.;
    • Matsutani, Tomoo;
    • Xu, Shuichan;
    • Wong, Lilly;
    • Liu, Yong;
    • Wu, Xiaoling;
    • Mortensen, Deborah S.;
    • Chopra, Rajesh;
    • Hege, Kristen;
    • Munster, Pamela N.
    Publication type:
    journal article
    13
    14
    15
    16

    Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

    Published in:
    2017
    By:
    • Infante, Jeffrey;
    • Patnaik, Amita;
    • Verschraegen, Claire;
    • Olszanski, Anthony;
    • Shaheen, Montaser;
    • Burris, Howard;
    • Tolcher, Anthony;
    • Papadopoulos, Kyriakos;
    • Beeram, Muralidhar;
    • Hynes, Scott;
    • Leohr, Jennifer;
    • Lin, Aimee;
    • Li, Lily;
    • McGlothlin, Anna;
    • Farrington, Daphne;
    • Westin, Eric;
    • Cohen, Roger;
    • Infante, Jeffrey R;
    • Verschraegen, Claire F;
    • Olszanski, Anthony J
    Publication type:
    journal article
    17
    18
    19
    20
    21
    22

    Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with <italic>BRAF</italic> V600–mutant tumours.

    Published in:
    British Journal of Clinical Pharmacology, 2018, v. 84, n. 4, p. 764, doi. 10.1111/bcp.13488
    By:
    • Nebot, Noelia;
    • Arkenau, Hendrik‐Tobias;
    • Infante, Jeffrey R.;
    • Chandler, Jason C.;
    • Weickhardt, Andrew;
    • Lickliter, Jason D.;
    • Sarantopoulos, John;
    • Gordon, Michael S.;
    • Mak, Gabriel;
    • St‐Pierre, Annie;
    • Tang, Lihua;
    • Mookerjee, Bijoyesh;
    • Carson, Stanley W.;
    • Hayes, Siobhan;
    • Grossmann, Kenneth F.
    Publication type:
    Article
    23

    Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum].

    Published in:
    International Journal of Nanomedicine, 2019, v. 14, p. 5751, doi. 10.2147/IJN.S207276
    By:
    • Wu, Huali;
    • Infante, Jeffrey R;
    • Keedy, Vicki L;
    • Jones, Suzanne F;
    • Chan, Emily;
    • Bendell, Johanna C;
    • Lee, Wooin;
    • Kirschbrown, Whitney P;
    • Zamboni, Beth A;
    • Ikeda, Satoshi;
    • Kodaira, Hiroshi;
    • Rothenberg, Mace L;
    • III, Howard A Burris;
    • Zamboni, William C
    Publication type:
    Article
    24

    Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.

    Published in:
    International Journal of Nanomedicine, 2015, v. 10, p. 1201, doi. 10.2147/IJN.S62911
    By:
    • Huali Wu;
    • Infante, Jeffrey R.;
    • Keedy, Vicki L.;
    • Jones, Suzanne F.;
    • chan, Emily;
    • Bendell, Johanna C.;
    • lee, Wooin;
    • Kirschbrown, Whitney P.;
    • Zamboni, Beth A.;
    • Ikeda, Satoshi;
    • Kodaira, Hiroshi;
    • Rothenberg, Mace L.;
    • Burris III, Howard A.;
    • Zamboni, William C.
    Publication type:
    Article
    25
    26
    27
    28
    29

    Prognostic Factors ofSurvival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer.

    Published in:
    Oncologist, 2015, v. 20, n. 2, p. 143, doi. 10.1634/theoncologist.2014-0394
    By:
    • Tabernero, Josep;
    • Chiorean, E. Gabriela;
    • Infante, Jeffrey R.;
    • Hingorani, Sunil R.;
    • Ganju, Vinod;
    • Weekes, Colin;
    • Scheithauer, Werner;
    • Ramanathan, Ramesh K.;
    • Goldstein, David;
    • Penenberg, Darryl N.;
    • Romano, Alfredo;
    • Ferrara, Stefano;
    • Von Hoff, Daniel D.
    Publication type:
    Article
    30

    Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 1, p. 182, doi. 10.1007/s10637-020-01000-6
    By:
    • Hecht, J. Randolph;
    • Papadopoulos, Kyriakos P.;
    • Falchook, Gerald S.;
    • Patel, Manish R.;
    • Infante, Jeffrey R.;
    • Aljumaily, Raid;
    • Wong, Deborah J.;
    • Autio, Karen A.;
    • Wainberg, Zev A.;
    • Bauer, Todd M.;
    • Javle, Milind;
    • Pant, Shubham;
    • Bendell, Johanna;
    • Hung, Annie;
    • Ratti, Navneet;
    • VanVlasselaer, Peter;
    • Verma, Rakesh;
    • Leveque, Joseph;
    • Rao, Sujata;
    • Oft, Martin
    Publication type:
    Article
    31

    Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 3, p. 844, doi. 10.1007/s10637-019-00832-1
    By:
    • Sandhu, Shahneen;
    • McNeil, Catriona M.;
    • LoRusso, Patricia;
    • Patel, Manish R.;
    • Kabbarah, Omar;
    • Li, Chunze;
    • Sanabria, Sandra;
    • Flanagan, W. Michael;
    • Yeh, Ru-Fang;
    • Brunstein, Flavia;
    • Nazzal, Denise;
    • Hicks, Rodney;
    • Lemahieu, Vanessa;
    • Meng, Raymond;
    • Hamid, Omid;
    • Infante, Jeffrey R.
    Publication type:
    Article
    32

    A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 6, p. 1016, doi. 10.1007/s10637-018-0591-z
    By:
    • Aghajanian, Carol;
    • Bell-McGuinn, Katherine M.;
    • Burris, Howard A.;
    • Siu, Lillian L.;
    • Stayner, Lee-Ann;
    • Wheler, Jennifer J.;
    • Hong, David S.;
    • Kurkjian, Carla;
    • Pant, Shubham;
    • Santiago-Walker, Ademi;
    • Gauvin, Jennifer L.;
    • Antal, Joyce M.;
    • Opalinska, Joanna B.;
    • Morris, Shannon R.;
    • Infante, Jeffrey R.
    Publication type:
    Article
    33
    34
    35
    36
    37

    Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.

    Published in:
    Targeted Oncology, 2022, v. 17, n. 4, p. 433, doi. 10.1007/s11523-022-00893-y
    By:
    • Girgis, Suzette;
    • Lin, Shun Xin Wang;
    • Pillarisetti, Kodandaram;
    • Banerjee, Arnob;
    • Stephenson, Tara;
    • Ma, Xuewen;
    • Shetty, Shoba;
    • Yang, Tong-Yuan;
    • Hilder, Brandi W.;
    • Jiao, Qun;
    • Hanna, Brett;
    • Adams III, Homer C;
    • Sun, Yu-Nien;
    • Sharma, Amarnath;
    • Smit, Jennifer;
    • Infante, Jeffrey R.;
    • Goldberg, Jenna D.;
    • Elsayed, Yusri
    Publication type:
    Article